Business
Unverified
Gathered automatically from the outlets below; our newsroom hasn't checked it yet.
Biotechs buck a sluggish IPO market, but investors should tread warily
While a number of IPOs have been pulled or delayed in 2026, the biotech sector has bucked the trend, with 26 companies debuting in U.S. markets.
